Endovascular middle cerebral artery embolic stroke model: a novel approach.

Thumbnail Image



Journal Title

Journal ISSN

Volume Title

Repository Usage Stats


Citation Stats


A video (video 1) describing a novel murine endovascular embolic stroke model is presented. Traditional middle cerebral artery (MCA) occlusion models include a blind insertion of a monofilament string12 into the common or external carotid artery with the expectation to selectively occlude the MCA. However, significant mortality occurs due to subarachnoid hemorrhage and variability in stroke size, possibly related to the filament's malposition-for example, external carotid or proximal internal carotid artery (ICA). Additionally, while the string is in place, it occludes the entire extracranial ICA affecting also the collateral pial circulation.neurintsurg;neurintsurg-2021-017370v1/V1F1V1Video 1Our model includes tail artery access, which tolerates several procedures facilitating survival studies. This model uses autologous blood3 4 clot deployed directly into the MCA, resembling what occurs in clinical practice. Autologous thrombi could be lysed with IA/IV tissue plasminogen activator.In summary, we describe a novel model that resembles real practice, permits multiple catheterizations, results in reliable embolization under fluoroscopic guidance and allows therapeutic interventions not available with traditional models.





Published Version (Please cite this version)


Publication Info

Gonzalez, L Fernando, David S Warner, Huaxing Sheng and Eduardo Chaparro (2021). Endovascular middle cerebral artery embolic stroke model: a novel approach. Journal of neurointerventional surgery. 10.1136/neurintsurg-2021-017370 Retrieved from https://hdl.handle.net/10161/23950.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.



Huaxin Sheng

Associate Professor in Anesthesiology

We have successfully developed various rodent models of brain and spinal cord injuries in our lab, such as focal cerebral ischemia, global cerebral ischemia, head trauma, subarachnoid hemorrhage, intracerebral hemorrhage, spinal cord ischemia and compression injury. We also established cardiac arrest and hemorrhagic shock models for studying multiple organ dysfunction.  Our current studies focus on two projects. One is to examine the efficacy of catalytic antioxidant in treating cerebral ischemia and the other is to examine the efficacy of post-conditioning on outcome of subarachnoid hemorrhage induced cognitive dysfunction.

Eduardo Chaparro

Research Scholar

Dr. Chaparro received his Medical Doctoral degree from Javeriana University in Bogota - Colombia and his Ph.D. in Medical Sciences with a focus on Physiology, Pharmacology, and Neuroscience from the University of South Florida in Tampa - Florida. He joined the Anesthesiology Department at USF for his graduate work to study the effects of anesthetics and anti-apoptotic compounds in brain ischemia. After completing his Ph.D., he came to Duke University for his post-doctoral training at the Multidisciplinary Neuroprotection Laboratory where he dedicated his time to testing drugs and devices in different animal models of neurological conditions getting special recognition for successfully testing the first hepatocyte growth factor mimetic in an animal model of transient cerebral ischemia. He also successfully tested a vestibular stimulator approved by the FDA for human use. After completing his post-doctoral training, Dr. Chaparro joined the Cerebrovascular and Skull Base Division at the Duke University Department of Neurosurgery where he has dedicated his career to testing treatments for neurovascular conditions including stroke, moyamoya disease, aneurysms, intra-cerebral hemorrhages, intravascular stent thrombogenicity, traumatic brain injury, and epilepsy. Dr. Chaparro is also an entrepreneur, and his interest in hypothermia as a treatment for neuronal inflammation, let him patent a brain-cooling device that has been successfully tested in non-human primates. He assembles a team of engineers, neuroscientists, and business experts to create Neurocool, a startup to develop the prototype further. As a CEO he is working on getting FDA approval and developing a human-compatible device aiming to help patients with central nervous system inflammatory conditions.

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.